Echo Therapeutics Inc.
Echo Therapeutics battles ‘dissident’ stockholder and pool-industry board nominee
Echo Therapeutics in midst of a proxy battle with Platinum Management | Medtech personnel moves for the week of Apr. 28, 2014
Echo Therapeutics in proxy battle with largest shareholder
Echo Therapeutics (NSDQ:ECTE) revealed this week that it is in the midst of a proxy battle with its largest shareholder, Platinum Management, which owns nearly 1/5th of the company’s stock.
Diabetes: Echo Therapeutics files for CE Mark approval for Symphony CGM system
Echo Therapeutics (NSDQ:ECTE) said it filed for CE mark approval in the European Union for its Symphony continuous glucose monitoring system.
Diabetes: Echo Therapeutics gains after inking China deal
Echo Therapeutics (NSDQ:ECTE) said it inked a deal to license its Symphony continuous glucose monitor for the Chinese market, sending share prices up this week.
Echo Therapeutics announces $15M offering
Echo Therapeutics (NSDQ:ECTE) is offering 3.2 million shares of its common stock in hopes of raising about $15 million.
Echo Therapeutics touts positive results for Symphony’s CE Mark trial
Echo Therapeutics (NSDQ:ECTE) revealed results for its Symphony continuous glucose monitoring system, touting positive findings from the CE Mark regulatory trial.
Echo Therapeutics fires a third of its workers | MassDevice.com On Call
MASSDEVICE ON CALL — Echo Therapeutics (NSDQ:ECTE) drops a few points after announcing plans for wide-scale cost-reductions that include layoffs for 1/3 of the company’s staff.
Echo Therapeutics rises on CEO Mooney’s sudden departure
Echo Therapeutics (NSDQ:ECTE) chairman, president & CEO Dr. Patrick Mooney handed back the keys to the corner office rather suddenly, the company announced today.